ResearchMoz

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

GBI Research
Published Date » 2014-08-21
No. Of Pages » N/A
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Introduction
2.1 Disease Introduction
2.2 Classification of Brain Tumors
2.3 Tumor Grading
2.4 Subtypes of Glioblastoma Multiforme
2.5 Etiology
2.6 Pathophysiology
2.6.1 Loss of Heterozygosity of Chromosome 10
2.6.2 Epidermal Growth Factor Receptor Amplification
2.6.3 Phosphatase and Tensin Homolog Mutation
2.6.4 Loss of p53 Function
2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function
2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation
2.7 Symptoms
2.8 Diagnosis
2.9 Prognosis
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Surgery
2.11.2 Radiation Therapy
2.11.3 Chemotherapy
2.11.4 Targeted Therapy
2.11.5 Drugs for Symptom Relief
2.11.6 Other Alternative Therapies
2.12 Treatment Algorithm
2.13 GBI Research Report Guidance

3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products
3.1 Key Marketed Products
3.2 Temodar (temozolomide) – Merck
3.3 Avastin (bevacizumab) – Roche
3.4 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan)
3.4.1 BiCNU (carmustine) – Bristol-Myers Squibb
3.4.2 Gliadel Wafer (carmustine in polifeprosan) – Eisai
3.5 Unlicensed/Off-Label Use in Glioblastoma Multiforme
3.5.1 Lomustine
3.5.2 Carboplatin
3.5.3 Teniposide
3.6 Comparative Efficacy and Safety
3.7 Unmet Needs

4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Pipeline
4.1 Overall Pipeline
4.2 Molecular Targets
4.3 Clinical Trials
4.3.1 Clinical Trial Size
4.3.2 Clinical Trial Duration
4.3.3 Failure Rate of Developmental Pipeline
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Pipeline Candidates
4.4.1 Rindopepimut (CDX-110) – Celldex Therapeutics
4.4.2 Avastin (bevacizumab) – Roche
4.4.3 Cotara – Peregrine Pharmaceuticals
4.4.4 BIOMAb (nimotuzumab) – BioCon
4.5 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Glioblastoma Multiforme Pipeline

5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 India
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Glioblastoma Multiforme Therapeutics in the Asia-Pacific Market to 2020
5.6.1 Drivers
5.6.2 Barriers

6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations
6.1 Major Co-Development Deals
6.1.1 Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical
6.1.2 Immatics Biotechnologies Enters into Agreement with Cancer Research UK
6.2 Major Licensing Deals
6.2.1 Eisai Received Marketing Authorization Holder License with Nobelpharma for Gliadel in Japan
6.2.2 Teva Pharma Enters into Agreement with Perrigo for Generic Temozolomide
6.2.3 SOM Biotech Enters into Licensing Agreement with Argon Pharma for SOM0777
6.2.4 ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania
6.2.5 Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children’s Hospital Medical Center
6.2.6 Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center

7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 All Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Phase I
7.4.4 Phase II
7.4.5 Phase III and Pre-Registration
7.4.6 Undisclosed stage of development
7.5 Market Forecasts to 2020
7.5.1 Asia-Pacific
7.5.2 Australia
7.5.3 China
7.5.4 India
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Forecasting
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Competitive Landscape
7.8 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

List of Tables

Table 1: Glioblastoma Multiforme, Classification of Brain Tumors by the American Association of Neurological Surgeons, 2014
Table 2: Glioblastoma Multiforme, World Health Organization Classification of Glioma, 2005
Table 3: Glioblastoma Multiforme, Karnofsky Performance Status Score (%), 1984
Table 4: Discovery
Table 5: Preclinical and IND/CTA-filed
Table 6: Phase I
Table 7: Phase II
Table 8: Phase III and pre-registration
Table 9: Undisclosed stage of development
Table 10: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Forecast Data, 2013–2020
Table 11: Glioblastoma Multiforme Therapeutics, Australia, Forecast Data, 2013–2020
Table 12: Glioblastoma Multiforme Therapeutics, China, Forecast Data, 2013–2020
Table 13: Glioblastoma Multiforme Therapeutics, India, Forecast Data, 2013–2020
Table 14: Glioblastoma Multiforme Therapeutics, Japan, Forecast Data, 2013–2020

List of Figures

Figure 1: Glioblastoma Multiforme, Genetic Pathways to Primary and Secondary GBM and the Incidence of Mutations, 2014
Figure 2: Glioblastoma Multiforme, Treatment Algorithm for Glioblastoma Multiforme, 2014
Figure 3: Glioblastoma Multiforme, Treatment Options for Recurrent Glioblastoma Multiforme, 2014
Figure 4: Glioblastoma Multiforme, Global, Historical Sales of Temodar ($m), 2008–2013
Figure 5: Glioblastoma Multiforme, Global, Historical Sales of Avastin ($bn), 2004–2013
Figure 6: Glioblastoma Multiforme, Global, Historical Sales of Gliadel Wafer ($m), 2003–2006
Figure 7: Glioblastoma Multiforme , Global, Heat Map for Marketed Products, 2013
Figure 8: Glioblastoma Multiforme, Global, Overall Pipeline, 2013
Figure 9: Glioblastoma Multiforme, Global, Program Type by Phase and Molecular Targets, 2013
Figure 10: Glioblastoma Multiforme, Global, Mean Clinical Trial Size by Molecule Type, 2006–2013
Figure 11: Glioblastoma Multiforme, Global, Mean Clinical Trial Duration by Molecule Type (Months), 2006–2013
Figure 12: Glioblastoma Multiforme, Global, Clinical Trial Failure Rate by Phase by Molecule Type and Reasons for Failure, 2006–2013
Figure 13: Glioblastoma Multiforme, Asia-Pacific, Heat Map for Pipeline Products, 2013
Figure 14: Glioblastoma Multiforme, Asia-Pacific, Product Competitiveness Framework, 2013
Figure 15: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000), 2013–2020
Figure 16: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Market Size ($m), 2013–2020
Figure 17: Glioblastoma Multiforme Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020
Figure 18: Glioblastoma Multiforme Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020
Figure 19: Glioblastoma Multiforme Therapeutics, Australia, Market Size ($m), 2013–2020
Figure 20: Glioblastoma Multiforme Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020
Figure 21: Glioblastoma Multiforme Therapeutics, China, Annual Cost of Therapy ($), 2013–2020
Figure 22: Glioblastoma Multiforme Therapeutics, China, Market Size ($m), 2013–2020
Figure 23: Glioblastoma Multiforme Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020
Figure 24: Glioblastoma Multiforme Therapeutics, India, Annual Cost of Therapy ($), 2013–2020
Figure 25: Glioblastoma Multiforme Therapeutics, India, Market Size ($m), 2013–2020
Figure 26: Glioblastoma Multiforme Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020
Figure 27: Glioblastoma Multiforme Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 28: Glioblastoma Multiforme Therapeutics, Japan, Market Size ($m), 2013–2020

Upcoming Reports:

Fatty Alcohols Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Fatty alcohols are oleochemicals which are colorless waxy solids primarily derived from natural fats and oils. In addition, fatty alcohols can be manufactured synthetically from petrochemicals such as olefins and paraffin. Fatty alcohols are mainly used in manufacture of detergents and surfactants. Moreover, they are used in various other applications such personal care products, textiles and leather, agriculture, polymer processing and printing. Fatty alcohols perform various functions such as solubilizing, floatation, lubricant, emulsifier and superfatting. Escalating demand...
Greece: soya beans market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the soya beans market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the soya beans market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
Outdoor Wi-Fi - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Wi-Fi technology is crucial for various systems such as Machine to Machine (M2M), Hot Spots, Outdoor Wi-Fi, Wi-Fi on the Go and In-Flight Wi-Fi. Outdoor Wi-Fi market is expected to grow at a substantial growth rate throughout the forecast period. Outdoor W-Fi technology is emerging across various verticals such as healthcare, education, public sector and travel and hospitality among others.  The global outdoor Wi-Fi market is segmented into three major categories, on the basis of product into: access points, Wlan controllers, wireless hotspot gateways, and others (repeaters,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Low Gas Prices Hurt Utahs Energy Industry
Dec 18, 2014  
Due to excessive petroleum on the global market, gas prices are heavily tumbling in several places of the world. This aspect could prove effective and great for consumers in most parts of the world, but it is not so for the Utah. The petroleum industry in Utah has a tough time with the state budget.  In Utah, the average gas prices have declined to around $2.64 a gallon. This has...
The 3 Dining Trend to Look Out For in 2015
Dec 17, 2014  
Dining is a vibrant, dynamic subject. You can never set down a list of definitive rules for it, and since it depends on our own fickle taste, it is always subject to drastic changes and welcoming to new trends. Here’s a list of dining trends that are on the cusp of becoming mainstream and will surely make that step up in the coming year. 1. Increasing Acceptance of Technology:...
Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...